Polymyositis/dermatomyositis-associated lung disease: analysis of a series of 81 patients

The objective of this study was to assess the prevalence, clinical, histological and immunological characteristics, and the long-term outcome of polymyositis-(PM) and dermatomyositis-(DM) associated lung disease, and to define subgroups of lung-associated inflammatory myopathies. This retrospective study included 81 consecutive patients diagnosed with PM/DM. Pulmonary involvement was systematically investigated in relation to clinical symptoms by chest radiography, high resolution computed tomography and pulmonary function testing. Anti-synthetase autoantibodies (ASA) were analysed by ELISAandconfirmedbyproteinandRNA immunoprecipitation methods. Statistical analyses were done with the Student t-test and Fisher exact test. Cumulative survival probabilities were estimated by the Kaplan-Meier method and Cox regression analysis. Fifty patients (61%) presented pulmonary involvement. Thirty-two (39%) had interstitial lung disease and five of them had devastating acute interstitial pneumonia with pneumomediastinum and an unfavorable prognosis. Histology showed diffuse alveolar damage in this subgroup and ASA were negative. Eighteen patients (22%) presented restrictive myopathic lung disease; in three of them respiratory muscles could not maintain ventilation. ASA were positive in 17 of the 50 patients (34%) and were significantly associated with interstitial lung disease (OR: 4.5 [95% CI: 1.3-15.3]), arthritis (OR: 6.0 [95% CI: 1.3-29.2]) and ‘mechanic hands’ (OR: 8.5 [95% CI: 1.7-41.4]); the presence of these autoantibodies did not imply worse survival prognosis. We concluded that clinical and immunological characteristics allowed the grouping of patients into different types of PM/DM lung-associated disease. Presence of ASA did not affect survival. ASA-negative patients with acute interstitial pneumonitis and pneumomediastinum had an unfavorable prognosis.

[1]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .

[2]  B. Hellmich,et al.  Interstitial lung disease in polymyositis and dermatomyositis , 2005, Current rheumatology reports.

[3]  M. Vilardell‐Tarrés,et al.  Refractory adult dermatomyositis with pneumatosis cystoides intestinalis treated with infliximab. , 2004, Rheumatology.

[4]  C. Korkmaz,et al.  Successful treatment of alveolar hypoventilation due to dermatomyositis with anti-tumour necrosis factor-alpha. , 2004, Rheumatology.

[5]  B. Michel,et al.  Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1. , 2004, Rheumatology.

[6]  V. Loustaud-Ratti,et al.  Refractory polymyositis responding to infliximab: extended follow-up. , 2004, Rheumatology.

[7]  S. Okada,et al.  Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. , 2003, Arthritis and rheumatism.

[8]  M. Netea,et al.  Successful Treatment of Dermatomyositis and Polymyositis with Anti-Tumor-Necrosis-Factor-Alpha: Preliminary Observations , 2003, European Neurology.

[9]  J. Biederer,et al.  Interstitial lung disease in polymyositis and dermatomyositis: clinical course and response to treatment. , 2003, Seminars in arthritis and rheumatism.

[10]  M. Labrador-Horrillo,et al.  The neural network as a predictor of cancer in patients with inflammatory myopathies. , 2002, Arthritis and rheumatism.

[11]  J. Ioannidis,et al.  Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease. , 2002, The Journal of rheumatology.

[12]  A. Nicholson,et al.  Lung fibrosis: new classifications and therapy. , 2001, Current opinion in rheumatology.

[13]  D. Schroeder,et al.  Polymyositis-dermatomyositis-associated interstitial lung disease. , 2001, American journal of respiratory and critical care medicine.

[14]  C. Korkmaz,et al.  Pneumomediastinum and subcutaneous emphysema associated with dermatomyositis , 2001 .

[15]  S. Nagai,et al.  Interstitial lung disease in polymyositis and dermatomyositis , 2000, Current opinion in rheumatology.

[16]  M. Vilardell‐Tarrés,et al.  Respiratory failure due to muscle weakness in inflammatory myopathies: maintenance therapy with home mechanical ventilation. , 2000, Rheumatology.

[17]  J. Vencovský,et al.  The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient , 2000, Annals of the rheumatic diseases.

[18]  T. Mimori,et al.  Anti-KS: identification of autoantibodies to asparaginyl-transfer RNA synthetase associated with interstitial lung disease. , 1999, Journal of immunology.

[19]  M. Schwarz The lung in polymyositis. , 1998, Clinics in chest medicine.

[20]  B. V. van Engelen,et al.  Dermatomyositis with subclinical myositis and spontaneous pneumomediastinum with pneumothorax: case report and review of the literature. , 1998, Clinical and experimental rheumatology.

[21]  W. Gross,et al.  Intravenous pulse cyclophosphamide in the treatment of interstitial lung disease due to collagen vascular diseases. , 1998, Arthritis and rheumatism.

[22]  B. Wallaert,et al.  Pulmonary involvement in polymyositis and in dermatomyositis. , 1998, The Journal of rheumatology.

[23]  B. Zweiman,et al.  Inflammatory myopathy, bronchiolitis obliterans/organizing pneumonia, and anti-Jo-1 antibodies--an interesting association , 1997, Clinical and diagnostic laboratory immunology.

[24]  Ò. Miró,et al.  Interstitial lung disease related to dermatomyositis. Comparative study with patients without lung involvement. , 1996, The Journal of rheumatology.

[25]  J. Roca,et al.  Standardization of the measurement of transfer factor (diffusing capacity) , 1993, European Respiratory Journal.

[26]  J E Cotes,et al.  Lung volumes and forced ventilatory flows , 1993, European Respiratory Journal.

[27]  J. Bosch,et al.  [Idiopathic inflammatory myopathy. Analysis of 31 patients]. , 1991, Revista clinica espanola.

[28]  T. Miyamoto,et al.  Interstitial lung disease in dermatomyositis: clinicopathological study. , 1987, The Journal of rheumatology.

[29]  W. J. Martin,et al.  Pulmonary disease in polymyositis/dermatomyositis: a clinicopathological analysis of 65 autopsy cases. , 1987, Annals of the rheumatic diseases.

[30]  D. Navajas,et al.  Spirometric reference values from a Mediterranean population. , 1986, Bulletin europeen de physiopathologie respiratoire.

[31]  I. Chalmers,et al.  Measurements of maximum respiratory pressures in polymyositis and dermatomyositis. , 1985, The Journal of rheumatology.

[32]  F. Arnett,et al.  Antibody to Jo-1 in polymyositis/dermatomyositis: association with interstitial pulmonary disease. , 1984, The Journal of rheumatology.

[33]  W. S. Fowler,et al.  The absorption of carbon monoxide by the lungs during breath-holding. , 1954, The Journal of clinical investigation.

[34]  T. Horie,et al.  Elevation of Serum Soluble Tumour Necrosis Factor Receptors in Patients with Polymyositis and Dermatomyositis , 2000, Clinical Rheumatology.

[35]  E. Gromnica-ihle,et al.  Clinical and Serological Aspects of Patients with Anti-Jo-1 Antibodies – an Evolving Spectrum of Disease Manifestations , 2000, Clinical Rheumatology.

[36]  M. Yamakido,et al.  Dermatomyositis associated with rapidly progressive fatal interstitial pneumonitis and pneumomediastinum. , 1999, Scandinavian journal of rheumatology.

[37]  Ò. Miró,et al.  [Clinical course of idiopathic inflammatory myopathies: complications, survival and prognostic factors]. , 1999, Medicina clinica.

[38]  T. Starzl,et al.  Tacrolimus in refractory polymyositis with interstitial lung disease. , 1999, Lancet.

[39]  K. Maeda,et al.  Cyclosporine treatment for polymyositis/dermatomyositis: is it possible to rescue the deteriorating cases with interstitial pneumonitis? , 1997, Scandinavian journal of rheumatology.